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Abstract
There is currently tremendous interest in developing anti-cancer therapeutics targeting cell
signaling pathways important for both cancer cell metabolism and growth. Several epidemi-
ological studies have shown that diabetic patients taking metformin have a decreased inci-
dence of pancreatic cancer. This has prompted efforts to evaluate metformin, a drug with
negligible toxicity, as a therapeutic modality in pancreatic cancer. Preclinical studies in cell
line xenografts and one study in patient-derived xenograft (PDX) models were promising,
while recently published clinical trials showed no benefit to adding metformin to combination
therapy regimens for locally advanced and metastatic pancreatic cancer. PDX models in
which patient tumors are directly engrafted into immunocompromised mice have been
shown to be excellent preclinical models for biomarker discovery and therapeutic develop-
ment. We evaluated the response of four PDX tumor lines to metformin treatment and found
that all four of our PDX lines were resistant to metformin. We found that the mechanisms of
resistance may occur through lack of sustained activation of adenosine monophosphate-
activated protein kinase (AMPK) or downstream reactivation of the mammalian target of
rapamycin (mTOR). Moreover, combined treatment with metformin and mTOR inhibitors
failed to improve responses in cell lines, which further indicates that metformin alone or in
combination with mTOR inhibitors will be ineffective in patients, and that resistance to met-
formin may occur through multiple pathways. Further studies are required to better under-
stand these mechanisms of resistance and inform potential combination therapies with
metformin and existing or novel therapeutics.
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Introduction
Pancreatic cancer is one of the most aggressive and lethal malignancies, with 80% of patients
presenting with locally advanced or metastatic disease that portends a 6–12 month median sur-
vival and a dismal 6% five-year survival rate [1]. Chemotherapy produces only modest
improvements in survival, and novel therapies are desperately needed to improve treatment
options for this large patient population [2]. There is currently tremendous interest in develop-
ing anti-cancer therapeutics that target cell signaling pathways important in both cell metabo-
lism and cell growth [3]. The 5' adenosine monophosphate-activated protein kinase (AMPK)
pathway has gained increasing interest, as AMPK physiologically inhibits the mammalian tar-
get of rapamycin (mTOR) to maintain homeostasis in conditions of decreased available cellular
energy sources [4, 5]. Studies have shown that mTOR signaling plays key roles in survival and
proliferation of malignant cells [6, 7]. Thus, AMPK activators have generated substantial inter-
est as potential antineoplastic agents that function by altering metabolism and inhibiting the
mTOR pathway [3].
Metformin is the first-line agent for treatment of type 2 diabetes mellitus. Metformin inhib-
its mitochondrial oxidative phosphorylation, thereby increasing the ratio of AMP to ATP [8,
9]. High levels of AMP activate AMPK, which then inhibits energy-consuming pathways such
as protein synthesis, in part by downregulating mTOR signaling by direct phosphorylation of
the tumor suppressor TSC2 and the mTOR binding partner Raptor [9–13]. The state of energy
conservation induced by metformin has been proposed to explain the cytostatic effect of met-
formin on cancer [9] and the apparent protective effect observed in diabetic patients treated
with metformin who subsequently develop pancreatic cancer [14].
Several epidemiological studies have indicated that patients with diabetes taking metformin
have a decreased incidence of pancreatic cancer [14–17]. This has prompted a great deal of
excitement to evaluate metformin, a widely used drug with negligible toxicity, as a therapeutic
modality in pancreatic cancer. There are currently 3 clinical trials evaluating metformin in
combination with various chemotherapies in pancreatic cancer (cancer.gov/clinicaltrials). Pre-
clinical studies in cell line xenografts and one recent study in patient-derived xenograft (PDX)
models have shown promise [18–22].
PDX models in which patient tumors are directly engrafted into immunocompromised
mice have been shown to recapitulate primary tumor architecture and genetic characteristics,
even after passaging and expanding the tumors in successive generations of mice [23, 24]. Fur-
thermore, PDX models are superior to traditional cell line xenografts, which are adapted to in
vitro growth and lack the heterogeneity of patient tumors, for evaluating responses to therapies
and novel biomarkers [23–27]. Until recently, there have been very limited studies of PDX
responses to many proposed oncological agents, and results for metabolic therapies like met-
formin are still severely lacking [27]. Thus, the objective of this study was to evaluate the
response of pancreatic cancer PDX models to metformin and to investigate metformin’s mech-
anism of action and compensatory resistance pathways.
Materials and Methods
Drugs and reagents
Metformin hydrochloride (Spectrum, New Brunswick, NJ, USA) was dissolved in phosphate-
buffered saline (PBS) for both in vitro and in vivo studies. Rapamycin (LC Laboratories,
Woburn, MA, USA) and BEZ235 (Center for Integrative Chemical Biology and Drug Discov-
ery, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA) were dissolved in dimethyl
sulfoxide (DMSO) for in vitro combination therapy studies. Antibodies against phosphorylated
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AMPKα (Thr172), AMPKα, AMPKα1, AMPKα2, phosphorylated mTOR (Ser2448), mTOR,
phosphorylated p70S6K (Thr389), p70S6K, phosphorylated 4E-BP1 (Thr37/46), and 4E-BP1
were from Cell Signaling (Beverly, MA, USA). Anti-glyceraldehyde phosphate dehydrogenase
(GAPDH) and horseradish peroxidase-conjugated goat anti-rabbit IgG were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Pierce1 ECLWestern Blotting Substrate was from
Thermo Scientific (Rockford, IL, USA). Apo-ONE Homogeneous Caspase-3/7 assay kit was
from Promega (Madison, WI, USA).
Cell culture and transduction with lentivirus
Pancreatic cancer cell lines Capan-2, CFPAC-1, HPAF-II, and SW1990 were obtained from the
American Type Culture Collection (ATCC), authenticated via short–tandem repeat (STR) pro-
filing (Genetica, Burlington, NC, USA), and tested negative for mycoplasma by indirect stain-
ing. Cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, California,
USA) at 37°C in a humidified 5% CO2 atmosphere.
The puromycin domain of the AMPKα1–859 pLKO.1 reporter plasmid (generously
donated by the laboratory of Channing Der, PhD at The University of North Carolina, Chapel
Hill, NC, USA) was replaced with a blasticidin domain by restriction enzyme digestion with
BamHI and KpmI. The second generation replication-incompetent lentivirus was generated in
293T cells with a four-plasmid system: the reporter plasmid, pMDL gag/pol RRE, pRSV-Rev,
and pCMV VSV-G. For transduction with lentivirus, 1×106 CFPAC-1 and HPAF-II cells were
seeded in 100 mm plates with lentivirus and a final polybrene concentration of 8 μg/mL. After
24 hours, the medium was replaced, and the cells were cultured for another 4 days with 2 μg/ml
of puromycin or 10 days with 10 μg/ml of blasticidin. The cells were trypsinized and analyzed by
western blotting to determine gene knockdown.
The expression vector for myc-mTOR transient overexpression was obtained from Addgene
(plasmid 1861, Cambridge, MA, USA). Transfection of 5x105 CFPAC-1 or HPAF-II cells was
carried out with Lipofectamine 2000 (Invitrogen, Carlsbad, California, USA) using manufac-
turer guidelines. Following 24 hour incubation, transfected cells were treated with 5 mMmet-
formin for an additional 24 hours, at which point cells were washed with PBS, harvested by
scraping, and stored at −80°C until protein isolation.
MTT assay for cell proliferation
To determine cell viability following drug treatments, 5x103 cells were plated in quadruplicate
into 96-well plates in 200 μl of RPMI 1640 medium and cultured overnight. The medium
was then replaced with fresh medium containing either PBS as a vehicle control, metformin
(0–5 mM), or metformin plus either rapamycin (0–80 μM) or BEZ235 (0–1 μM). After an addi-
tional 48 hour incubation, 50 μl of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) dissolved in PBS at pH 7.4 was added to each well. Following 1 hour
incubation, the culture medium and MTT reagent was aspirated and 200 μl of dimethyl sulfox-
ide was added to each well and mixed thoroughly. The absorbance at OD560 nm was measured
using a Synergy 2 plate reader (BioTek, Winooski, VT, USA). Relative proliferation at each
drug concentration was calculated according to the formula: 100%  (experimental OD560 /
vehicle OD560). Statistical significance was determined using one-way ANOVA analysis with
Dunnett’s multiple comparisons test. For combination therapy studies, synergy was assessed
using Compusyn software employing the Chou-Talalay median effect principle (ComboSyn,
Inc. Paramus, NJ, USA). All assays were performed in triplicate.
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Western blot conditions
After the indicated time of incubation with metformin, cells were washed with PBS, harvested
by scraping, and then lysed in 200 μL RIPA buffer containing 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1% Triton X, 1 mM NaF, and 0.25% Na deoxycholate and prote-
ase inhibitors. Protein extracts (30 μg) were electrophoresed on 10% SDS polyacrylamide gels
and electrotransferred to polyvinylidene difluoride (PVDF) membranes. For determination
of knockdown of AMPKα1 and AMPKα2, membranes were blocked with 5% non-fat dried
milk in Tris-buffered saline and then incubated overnight at 4˚C with 1:1000 dilutions of
anti-AMPKα1, anti-AMPKα2, and anti-AMPKα antibodies. For cell and tissue lysates isolated
following metformin treatments, membranes were incubated at 4°C overnight with 1:1000
dilutions of anti-phospho-mTOR, anti-mTOR, anti-phospho-p70S6K, anti-p70S6K, anti-
phospho-4E-BP1, anti-4E-BP1, anti-phospho-AMPKα, and anti-AMPK antibodies. Mem-
branes were then washed and incubated with a 1:5000 dilution of horseradish peroxidase-
conjugated goat anti-rabbit secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Immunoreactive bands were detected by chemiluminescence using the Pierce1 ECL
Western Blotting Substrate. Intensity of each immunoreactive band was quantified by densi-
tometry using Image J software (NIH, Bethesda, Maryland, USA), and expressed relative to the
PBS-treated cells or mice. GAPDH was used to ensure equivalent protein loading. Statistical
significance was determined using Student’s t-tests for two sample comparisons and one-way
ANOVA analysis with Dunnett’s multiple comparisons test for three or more sample
comparisons.
PDX cohort expansion
Pancreatic ductal adenocarcinoma tissue from de-identified patients with localized pancreatic
cancer who underwent curative surgical resection were obtained from the University of North
Carolina Institutional Review Board (IRB) approved Tissue Procurement Facility after IRB
approval (08–1153). Tumor tissue was engrafted subcutaneously into the flanks of NSG/NOD
mice, expanded, and passaged over time, as described previously [28, 29]. 7–8 week old Nu/nu
mice with an average weight of 18–20 g were used in all experiments. All animal experiments
were carried out in accordance with the U.S. National Institutes of Health (NIH) Guide for the
Care and Use of Laboratory Animals under protocols approved by the University of North
Carolina Institutional Animal Care and Use Committee (12–314).
Metformin treatment of PDX cohort
Treatment was started after engrafted tumors grew to a median tumor size of 108 mm3. At
least five mice were included in each treatment group for each PDX tumor line. Mice were
treated with metformin (200 or 400 mg/kg) or PBS (20 μl/g) by once daily oral gavage. The first
day of treatment was designated as day 0 and treatment was continued for 28 days. Tumor vol-
ume (V) was measured twice per week using calipers, and calculated as (length×width2)/2. Ani-
mal body weights were measured once weekly. Statistical significance was determined using
one-way ANOVA analysis with Dunnett’s multiple comparisons test. Tumor tissue was col-
lected two hours after the last treatment and cut into two parts: one part was snap-frozen in liq-
uid nitrogen and stored at −80°C until protein isolation, while the second part was fixed in
10% formalin and paraffin embedded (FFPE). FFPE tissue blocks were sectioned and stained
with hematoxylin and eosin for histopathological evaluation.
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Results
Metformin does not inhibit growth of PDX tumors
We evaluated the response of four pancreatic cancer PDX tumor lines to metformin (200 and
400 mg/kg) for 28 days. These doses were chosen as higher doses have been shown to be neces-
sary in mice to produce a decrease in blood glucose in diabetic animals [19, 30, 31]. In addition,
higher doses of metformin (0.1% w/w) have been shown to increase the longevity of mice [32].
No tumor growth inhibition or regression was seen in any of the four PDX tumor lines at any
time point measured (Fig 1). No change in body weights occurred over the course of the study
and tumor architecture remained grossly unchanged following 28 days of treatment as assessed
by hematoxylin and eosin staining (S1 Fig).
Activation of AMPK and inhibition of p70S6K phosphorylation in PDX
tumors is not sustained after a 28 day treatment with metformin
To determine whether metformin treatment altered AMPK and mTOR signaling, we evaluated
all four PDX tumor lines for phosphorylation of AMPK (Thr172) and p70S6K (Thr389) at the
end of the 28-day treatment (Fig 2A and 2B and S2 Fig). In this long-term treatment cohort, no
Fig 1. Metformin does not inhibit growth of PDX tumors. No significant growth inhibition was observed in four different pancreatic cancer PDX tumor lines
at any time point during a 28 day treatment course with 200 mg/kg or 400 mg/kg metformin administered by daily oral gavage.
doi:10.1371/journal.pone.0147113.g001
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Fig 2. Activation of AMPK and inhibition of p70S6K phosphorylation in PDX tumors is not sustained after 28 days of metformin treatment.
Phosphorylation of AMPKα and p70S6K in (A) P505 and (B) P710 PDX tumors after 28 day treatment with 400 mg/kg metformin. Phosphorylation of AMPKα
and p70S6K in (C) P505 and (D) P710 PDX tumors after 3 day treatment with 400 mg/kg metformin (*p<0.05).
doi:10.1371/journal.pone.0147113.g002
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change in phosphorylation of AMPK and p70S6K was seen in the metformin compared to the
vehicle treated tumors. We then evaluated the effect of metformin on two PDX tumors after
only 3 days of treatment. In contrast to the long-term treatment tumors, the short-term treat-
ment tumors showed increased phosphorylation of AMPK and decreased phosphorylation of
p70S6K (Fig 2C and 2D).
Metformin inhibits growth and alters AMPK and mTOR signaling in
pancreatic cancer cell lines
Since the lack of sustained response in our PDX models was surprising, we next examined
the effects of metformin on the proliferation of four pancreatic cancer cell lines (Capan-2,
CFPAC-1, HPAF-II, and SW1990). Metformin inhibited cell proliferation in a dose-dependent
fashion in all four cell lines (Fig 3A). Metformin treatment activated AMPK as determined by
phosphorylation of AMPK at Thr(172) in all cell lines tested, with a peak activation occurring
at 4–8 hours after treatment (Fig 3B). Given that AMPK activation is known to inhibit mTOR,
we further analyzed the effects of metformin treatment on the phosphorylation status of
mTOR and its downstream targets p70S6K and 4E-BP1. Interestingly, we observed a delayed
inhibition of mTOR and downstream target phosphorylation, with the nadir of observed phos-
phorylation of p70S6K and 4E-BP1 occurring at 48 hours in both CFPAC-1 and HPAF-II cells
(Fig 3C and 3D).
AMPK is only partially required for the anti-proliferative effect of
metformin
The anti-proliferative effect of metformin has been primarily attributed to its ability to activate
the AMPK pathway. We hypothesized that the lack of sustained AMPK activation seen in all
four PDX tumor lines may explain the lack of tumor growth response. Thus, we performed
shRNA-induced knockdown of one or both of the catalytic subunits of AMPK in pancreatic
cancer cell lines to determine whether the anti-proliferative effects of metformin would be
affected. We found that knockdown of AMPK α1 and/or AMPK α2 partially but not
completely reversed metformin’s ability to inhibit cell proliferation (Fig 4A and 4B).
Metformin appears to act on mTOR in an AMPK-independent manner
We next investigated whether the lack of sustained p70S6K inhibition seen in the P710 PDX
tumor line despite evidence of some sustained AMPK activation may have been due to an
AMPK-independent mechanism. We evaluated the effect of metformin on phosphorylation of
mTOR and p70S6K following knockdown of AMPK α1 and/or AMPK α2. CFPAC-1 and
HPAF-II cell lines with stable knockdown of NS, AMPK α1 and/or AMPK α2 (Fig 4A) were
treated with 5 mMmetformin (Fig 4B and 4C). In both cell lines, knockdown of one or both
subunits did not rescue the ability of metformin to inhibit growth or phosphorylation of
mTOR and p70S6K, suggesting that the ability of metformin to inhibit mTOR and p70S6K is
at least partially independent of AMPK activation in these cell lines.
mTOR overexpression is sufficient to overcome the anti-proliferative
effects of metformin, but combinatorial treatment with metformin and
mTOR inhibitors does not produce synergy
Because metformin failed to sustain inhibition of the mTOR pathway as measured by p70S6K
phosphorylation in our long-term metformin treated PDX tumors, and because of our findings
that metformin-induced mTOR inhibition was at least partially AMPK-independent, we next
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determined whether mTOR activation alone was sufficient to abrogate the effects of metfor-
min. We found that overexpression of mTOR using a myc-mTOR construct was sufficient to
produce complete resistance growth inhibition and to limit the decrease in p70S6K phosphory-
lation following metformin treatment (Fig 5A and 5B). To determine whether combining met-
formin with targeted mTOR inhibitors may be a logical therapeutic strategy, we treated cell
lines with constant-ratio doses of metformin and either the allosteric mTOR inhibitor
Fig 3. Metformin inhibits growth and alters AMPK andmTOR signaling in pancreatic cancer cell lines. (A) Cells were plated in quadruplicate into
96-well plates at a density of 5x103 per well, incubated overnight, and then treated with media containing either PBS as a vehicle control or different
concentrations of metformin (0–5 mM). After 48 hours, proliferation indices were determined using the MTT assay and normalized to those of the vehicle-
treated cells. All assays were performed in triplicate. (B) Phosphorylation of AMPKα and total AMPKα at various time points after treatment with 5 mM
metformin. Treatment began at 0 hours (hrs). (C) Phosphorylation of mTOR, p70S6K, and 4E-BP1 at various time points after treatment with 5 mM
metformin. (D) Densitometry of phosphorylated AMPKα, mTOR, p70S6K, and 4E-BP1 relative to total levels shown in (B) and (C).
doi:10.1371/journal.pone.0147113.g003
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Fig 4. AMPK is only partially required for the anti-proliferative effects of metformin. (A) shRNA knockdown of AMPKα subunits in CFPAC-1 and
HPAF-II cell lines. (B) Proliferation of CFPAC-1 and HPAF-II cell lines with stable knockdown of AMPKα subunits after treatment with different concentrations
of metformin (0–5 mM). (C) Phosphorylation of mTOR and p70S6K in CFPAC-1 and HPAF-II cell lines with stable knockdown of AMPKα subunits.
doi:10.1371/journal.pone.0147113.g004
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rapamycin or the catalytic mTOR inhibitor BEZ235, which are known to inhibit pancreatic
cancer cell line growth. Growth inhibition was not enhanced at any dose combination relative
to single drug treatment, and no synergism between metformin and either mTOR inhibitor
was calculated at any dose using the Chou-Talalay median effect equation (Fig 5C and 5D).
Fig 5. mTOR expression is sufficient to promote resistance to metformin in cell lines, but combinatorial treatment with metformin andmTOR
inhibitors does not produce synergy. (A) Phosphorylation of p70S6K in and (B) proliferation of HPAF-II cells after treatment with 5 mMmetformin following
transient expression of a transfected myc-mTOR construct. Using the median effect equation calculation for combination index (CI) following 3 day treatment
with constant-ratio doses of metformin and either (C) the allosteric mTOR inhibitor rapamycin or (D) the catalytic mTOR inhibitor BEZ235 failed to produce
synergy (CI<1) at any dose combination. CI values at 50% growth inhibition: (C) CFPAC-1 1.54, HPAF-II 1.43; (D) CFPAC-1 1.30, HPAF-II 1.29. (*p<0.050,
**p<0.005, ***p<0.001).
doi:10.1371/journal.pone.0147113.g005
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Discussion
Epidemiological studies in diabetic patients have found that patients treated with metformin
have a decreased incidence of multiple cancers, including pancreatic cancer [14–17]. Several
preclinical studies of metformin as an anti-cancer therapeutic have been promising, demon-
strating impressive tumor growth inhibition [20, 22, 33] and apoptosis [34] of pancreatic can-
cer cell lines. However, cell line xenografts have been generally unreliable predictors of drug
responses in humans. Lonardo et al. evaluated the effect of metformin on four pancreatic can-
cer PDX tumor lines and, similar to previous cell line xenograft studies, found substantial
growth inhibition [21]. In contrast, emerging clinical trials evaluating metformin in pancreatic
cancer have tempered the optimism created by this preclinical work. A double-blind, random-
ized, placebo-controlled phase II trial evaluating metformin in combination with gemcitabine
and erlotinib in patients with advanced pancreatic cancer showed no difference in outcome as
a result of metformin treatment [35]. Another phase II trial combining metformin with pacli-
taxel in patients with gemcitabine-refractory disease failed to meet its primary endpoint of dis-
ease control rate [36].
In this study, we observed a uniform lack of response to metformin in the four PDX tumor
lines that we evaluated. Several potential reasons exist for the disparate results between previ-
ous preclinical work compared to our study and recent clinical trials. First, PDX tumors are
inherently highly heterogeneous because PDX tumors are passaged in bulk and are representa-
tive ‘biopsies’ of similarly heterogeneous source patient tumors. Second, although the dose
range in our study overlaps with previous studies, the pharmacokinetics of metformin uptake
are still unclear [37]. Tumor microenvironment and stromal content appear to influence met-
formin’s access to tumor cells, which may lead to different outcomes between studies [21].
Third, the tumor volume at which treatment was initiated varies between studies, which may
affect tumor composition, specifically the cancer stem cell burden. Lonardo et al. and others
have shown that only this stem cell subpopulation undergoes apoptosis as a result of metfor-
min treatment, while the vast majority of tumor cells experience reversible growth arrest [18,
21]. Interestingly, although Lonardo et al. found that metformin was able to initially slow PDX
tumor growth, they noted that all PDX tumors eventually progressed on therapy [21], suggest-
ing that metformin monotherapy will not be effective in patients.
To gain insight into possible mechanisms of resistance, we further evaluated two of our four
PDX lines and found that resistance to metformin may be multifactorial and tumor-dependent.
For example, in P505, AMPK activation was not sustained whereas in P710, continued tumor
growth occurred despite some sustained AMPK activation. Our subsequent results in cell lines
suggest that this may be for two reasons. First, the effect of metformin on cell proliferation
appears to be only partially AMPK-dependent. Second, the ability of metformin to inhibit the
mTOR pathway in pancreatic cancer also appears to be only partially AMPK-dependent.
Across cancer types, the degree to which metformin relies upon AMPK activation to inhibit
growth and alter mTOR/p70S6K signaling is unclear and likely cell type-dependent. Inhibition
of AMPK expression via silencing of the catalytic AMPK α subunit using specific inhibitors of
AMPK or knockout of LKB1, the upstream signal for AMPK activation, reversed the anti-pro-
liferative effects of metformin in breast and ovarian cancer cells [38–40]. Conversely, Ben
Sahra et al. showed that downregulation of AMPK had no effect on metformin’s ability to
inhibit prostate cancer cell growth and mTOR signaling [41]. Instead, they found that metfor-
min led to mTOR inhibition and cell-cycle arrest by activating the mTORC1 inhibitor REDD1
[42]. Other studies in breast and ovarian cancer cell lines have also found that the effects of
metformin may be only partially dependent on AMPK activation [43, 44]. The anti-prolifer-
ative effect of metformin was maintained in the ovarian cancer cell line A2780 despite siRNA
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silencing of AMPKα1. In addition, metformin treatment was able to attenuate proliferation of
both AMPKα1/2 wild-type and AMPKα1/2 deficient mouse embryonic fibroblasts (MEFs),
although AMPKα1/2 deficient MEFs were slightly less sensitive to metformin [43]. In breast
cancer cell lines, inhibition of HER2 by metformin was found to be completely AMPK-inde-
pendent [44]. Recent studies in pancreatic cancer cell lines found that metformin may inhibit
growth independently of AMPK through upregulation of miR-26a [45], while metformin’s
effects on pancreatic cancer stem cells may be mediated through reexpression of specific miR-
NAs [18]. These results suggest that modulation of miRNA expression may be yet another
important mechanism underlying the biological effects of metformin.
Taken together with the above studies, our results that knockdown of AMPK subunits did
not rescue the inhibitory effects of metformin on mTOR/p70S6K phosphorylation but that
mTOR reexpression was able to reverse the anti-proliferative effects of metformin, suggest that
the activation of AMPK and inhibition of the mTOR/p70S6K pathway by metformin are inde-
pendent events that may both contribute to cancer cell growth inhibition. Moreover, regulation
of AMPK by metformin may be cell type dependent, and in pancreatic cancer, the anti-prolifer-
ative effects of metformin may be partially or largely AMPK-independent.
Overall, our study shows that although metformin inhibits pancreatic cancer cell line prolif-
eration, its effect on patient tumors will likely be transient and much more complex. While
resistance mechanisms likely involve mTOR pathway activation, simultaneous treatment with
metformin and mTOR inhibitors may do little to enhance the efficacy of either therapy. Fur-
ther studies are needed in order to determine whether metformin may someday provide benefit
to pancreatic cancer patients by leveraging its complex metabolic and signaling effects in com-
bination with chemotherapeutics or targeted therapies.
Supporting Information
S1 Fig. Long-term metformin treatment does not affect mouse weight or tumor histology.
(A) Weights of mice over a 28 day treatment course with either 200 mg/kg or 400 mg/kg met-
formin shown relative to baseline weights. Hematoxylin and eosin staining of (B) P505 and (C)
P710 patient-derived xenograft tumors following 28 day treatment with vehicle (left panels) or
400 mg/kg metformin (right panels) show no difference in tumor architecture, ductal forma-
tion, or stromal content. Scale bars are 300 μm.
(TIF)
S2 Fig. Activation of AMPK and inhibition of p70S6K phosphorylation in PDX tumors is
not sustained after 28 days of metformin treatment. Phosphorylation of AMPKα and
p70S6K in (A) P722 and (B) PT4 PDX tumors after 28 day treatment with 400 mg/kg metfor-
min.
(TIF)
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